<DOC>
	<DOCNO>NCT00004017</DOCNO>
	<brief_summary>RATIONALE : Radiolabeled monoclonal antibody locate tumor cell deliver tumor-killing substance without harm normal cell . This may effective treatment type brain tumor . PURPOSE : Phase II trial study effectiveness radiolabeled monoclonal antibody treat patient glioblastoma multiforme anaplastic astrocytoma .</brief_summary>
	<brief_title>Radiolabeled Monoclonal Antibody Treating Patients With Glioblastoma Multiforme Anaplastic Astrocytoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine median time disease progression patient newly diagnose unresectable glioblastoma multiforme ( GBM ) , recurrent GBM , recurrent anaplastic astrocytoma treat interstitial iodine I 131 monoclonal antibody TNT-1/B . - Determine median survival time patient treated regimen . - Determine safety regimen term neurotoxicity , renal , hepatic , hematologic , biochemical profile patient . - Confirm maximum tolerate dose regimen patient . - Optimize drug delivery regimen patient . - Assess response patient term MRI measure gadolinium enhanced tumor volume gadolinium enhance tumor area 8 12 week follow last dose study drug . OUTLINE : This multicenter study . Patients undergo stereotactic implantation 2 interstitial catheter tumor bed . One day later , patient receive iodine I 131 monoclonal antibody TNT-1/B interstitially approximately 24 hour . At select center , 3 additional group 3 patient receive study drug 48 hour . Catheters remove 1 day completion infusion . A gadolinium enhance MRI perform week 8 . Patients partial response , minimal response , stable disease repeat treatment week 9 . Patients complete response , progressive disease , unacceptable toxicity receive additional treatment . Patients follow every month disease progression . All patient regardless disease progression retreatment follow 36 week . PROJECTED ACCRUAL : A total 60 patient ( 20 patient newly diagnose unresectable glioblastoma multiforme [ GBM ] ; 20 patient recurrent GBM ; 20 patient recurrent anaplastic astrocytoma ) accrue study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm newly diagnose unresectable glioblastoma multiforme ( GBM ) , recurrent GBM , recurrent anaplastic astrocytoma ( AA ) MRI scan document gadolinium enhance tumor volume least 5 cm3 , great 60 cm^3 Recurrent GBM AA must document MRI recent treatment plan surgical debulking At least 5 day since prior surgical debulking No plan resection newly diagnose GBM study No bilateral noncontiguous gadolinium enhance tumor No satellite lesion great 1.5 cm anticipate location interstitial catheter tip No 2 satellite lesion PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Platelet count least 100,000/mm^3 Absolute neutrophil count least 1,500/mm^3 WBC least 3,000/mm^3 Hepatic : Hepatitis B surface antigen negative Bilirubin great 2.5 time upper limit normal ( ULN ) SGOT SGPT great 3 time ULN Alkaline phosphatase great 3 time ULN Lactic dehydrogenase great 3 time ULN Prothrombin time great 1.5 time ULN Renal : Creatinine clearance least 50 mL/min Cardiovascular : No significant unstable cardiovascular disease No New York Heart Association class III/IV heart disease No evidence myocardial infarction within past 3 month Other : Not pregnant Negative pregnancy test Fertile patient must use effective contraception Human antichimeric antibody ( HACA ) titer great 48 ng/mL No anatomical physiological consideration would preclude study participation No active autoimmune disease , active infection , traumatic injury require treatment HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior intravenous chemotherapy Gliadel wafer Endocrine therapy : Not specify Radiotherapy : At least 8 week since prior external beam gamma knife radiotherapy Surgery : See Disease Characteristics Other : At least 30 day since prior investigational treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2003</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>